FLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.

The Food and Drug Administration (FDA) has granted approval to mFLUSIVA, Moderna's mRNA-based seasonal influenza vaccine, making it the first flu shot built on the same technology behind the company's ...

Moderna (MRNA) valuation in focus: weak Q2, cash outlook, FDA win for mFLUSIVA, pipeline risks and sales hurdles.

Moderna’s mFLUSIVA is the first mRNA vaccine approved for seasonal flu. Its route to approval was unusual, with the FDA ...

At any given time, somewhere in the world, it’s flu season. One of humanity’s oldest infectious scourges, influenza has ...

Millions of older Americans will have access to a new type of influenza vaccine after the Food and Drug Administration ...

Researchers found no major safety concerns. Common short-term side effects included pain at the injection site, tiredness, ...

Vaccine makers can produce mRNA shots faster than those made with older technology, which could cut the risk of a mismatch ...

FDA clears Moderna's first mRNA flu vaccine for adults 50+, showing 27% higher efficacy than standard shots, ahead of the ...

Sara Hassan is a Digital Editor/Reporter at The World. She has more than two decades of journalism experience, as a writer, photographer, copy editor, reporter and field producer for TV, radio, ...

The Food and Drug Administration this week approved the first mRNA flu vaccine for adults 50 and older. Health experts lauded ...